We are developing ricolinostat to treat diabetic, chemotherapy-induced and inherited peripheral neuropathies. Ricolinostat, an oral, selective histone deacetylase 6 (HDAC6) inhibitor, has previously been clinically evaluated in over 250 patients with hematologic cancer and has demonstrated an excellent safety profile.
Inhibition of HDAC6 is a novel approach to restoring normal nerve function for the potential treatment of p...
We are developing ricolinostat to treat diabetic, chemotherapy-induced and inherited peripheral neuropathies. Ricolinostat, an oral, selective histone deacetylase 6 (HDAC6) inhibitor, has previously been clinically evaluated in over 250 patients with hematologic cancer and has demonstrated an excellent safety profile.
Inhibition of HDAC6 is a novel approach to restoring normal nerve function for the potential treatment of peripheral neuropathies by reestablishing the transport function of microtubules. Neurons conducting signals to and from the spinal cord into the feet and hands, are the longest cells in the body.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.